ELTP - Elite Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0888
0.0000 (0.00%)
As of 1:34PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0888
Open0.0889
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0770 - 0.0889
52 Week Range0.0700 - 0.1400
Volume225,248
Avg. Volume708,940
Market Cap72.771M
Beta (3Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Elite Pharmaceuticals and SunGen Pharma File ANDA for an Antibiotic

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of an antibiotic product. This is the third ANDA that Elite co-developed and filed with SunGen Pharma, LLC (“SunGen”).  According to QVIA (formerly QuintilesIMS Health) data the branded product for this antibiotic and its equivalents had total annual U.S. sales of approximately $94 million for the twelve months ending September 30, 2018.

  • GlobeNewswire2 months ago

    Elite Pharmaceuticals Receives FDA Approval for Hydrocodone and Acetaminophen Combo

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Company’s abbreviated new drug application (ANDA) for a generic version of Norco (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. The combination products of hydrocodone and acetaminophen have total annual US sales of approximately $447 million according to IQVIA (formerly QuintilesIMS Health) data. “This is our fourth product approval in 2018 with four additional ANDAs and an NDA for SequestOx™ currently filed with the FDA,” stated Nasrat Hakim, President and CEO of Elite.

  • GlobeNewswire2 months ago

    Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2019 Ended September 30, 2018 and Provides Conference Call Information

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the second quarter of fiscal year 2019 ended September 30, 2018 (“Second Quarter”). Consolidated revenues for the Second Quarter were $1.4 million, a decrease of approximately 16% as compared to revenues for the comparable quarter of the prior fiscal year.  The decrease in revenues was largely attributed to lower revenues received from the manufacture of generic methadone, hydromorphone and phentermine. Elite continues to invest in product development as $2.5 million was devoted to research and development expenses.  During the current fiscal year, Elite received FDA approval for generic Oxycodone/Acetaminophen and generic Methadone, achieved commercial launch of its methadone products  and conducted several successful bio-equivalence studies.

  • GlobeNewswire2 months ago

    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2019 Financial Results on November 12, 2018

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the second quarter financial results of the 2019 fiscal year will be released on Friday, November 9, 2018. Elite’s pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid.  These products include sustained release oral formulations of opioids for the treatment of chronic pain.

  • GlobeNewswire3 months ago

    Elite Pharmaceuticals Launches Generic Methadone Tablets

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced the commercial launch of generic methadone hydrochloride 5mg and 10 mg tablets by Glenmark Pharmaceuticals, Inc., USA (“Glenmark”), Elite’s marketing alliance partner. Methadone can also be used for detoxification treatment of opioid addiction (heroin or other morphine-like drugs) or maintenance treatment of opioid addiction in conjunction with appropriate social and medical services. Through this alliance, Glenmark will sell and distribute certain of Elite’s generic products, including methadone, for which Elite will receive manufacturing and license fees.

  • ACCESSWIRE5 months ago

    Elite Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 10, 2018 at 11:00 AM Eastern ...

  • ACCESSWIRE11 months ago

    New Research: Key Drivers of Growth for U.S. Stem Cell Inc. and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of U.S. Stem Cell Inc. ( OTCQB: USRM ) and Elite Pharmaceuticals Inc. ...

  • ACCESSWIRE11 months ago

    Elite Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 12, 2018 at 11:30 AM ...